Logo image of SLDB

SOLID BIOSCIENCES INC (SLDB) Stock Fundamental Analysis

USA - NASDAQ:SLDB - US83422E2046 - Common Stock

4.06 USD
-0.16 (-3.68%)
Last: 11/7/2025, 7:11:41 PM
4.14 USD
+0.08 (+1.97%)
After Hours: 11/7/2025, 7:11:41 PM
Fundamental Rating

3

Overall SLDB gets a fundamental rating of 3 out of 10. We evaluated SLDB against 534 industry peers in the Biotechnology industry. SLDB has a great financial health rating, but its profitability evaluates not so good. SLDB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLDB had negative earnings in the past year.
In the past year SLDB has reported a negative cash flow from operations.
In the past 5 years SLDB always reported negative net income.
SLDB had a negative operating cash flow in each of the past 5 years.
SLDB Yearly Net Income VS EBIT VS OCF VS FCFSLDB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -49.98%, SLDB perfoms like the industry average, outperforming 50.37% of the companies in the same industry.
SLDB's Return On Equity of -59.66% is fine compared to the rest of the industry. SLDB outperforms 61.61% of its industry peers.
Industry RankSector Rank
ROA -49.98%
ROE -59.66%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
SLDB Yearly ROA, ROE, ROICSLDB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLDB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLDB Yearly Profit, Operating, Gross MarginsSLDB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, SLDB has more shares outstanding
The number of shares outstanding for SLDB has been increased compared to 5 years ago.
Compared to 1 year ago, SLDB has an improved debt to assets ratio.
SLDB Yearly Shares OutstandingSLDB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLDB Yearly Total Debt VS Total AssetsSLDB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.69, we must say that SLDB is in the distress zone and has some risk of bankruptcy.
SLDB has a Altman-Z score (-0.69) which is in line with its industry peers.
There is no outstanding debt for SLDB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.69
ROIC/WACCN/A
WACCN/A
SLDB Yearly LT Debt VS Equity VS FCFSLDB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 9.34 indicates that SLDB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.34, SLDB is in the better half of the industry, outperforming 79.59% of the companies in the same industry.
SLDB has a Quick Ratio of 9.34. This indicates that SLDB is financially healthy and has no problem in meeting its short term obligations.
SLDB has a better Quick ratio (9.34) than 79.78% of its industry peers.
Industry RankSector Rank
Current Ratio 9.34
Quick Ratio 9.34
SLDB Yearly Current Assets VS Current LiabilitesSLDB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

SLDB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLDB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.05% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y32.98%
EPS Next 2Y16.08%
EPS Next 3Y12.32%
EPS Next 5Y14.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLDB Yearly Revenue VS EstimatesSLDB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2025 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
SLDB Yearly EPS VS EstimatesSLDB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLDB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLDB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLDB Price Earnings VS Forward Price EarningsSLDB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLDB Per share dataSLDB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

SLDB's earnings are expected to grow with 12.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.08%
EPS Next 3Y12.32%

More info and screens

0

5. Dividend

5.1 Amount

SLDB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLID BIOSCIENCES INC

NASDAQ:SLDB (11/7/2025, 7:11:41 PM)

After market: 4.14 +0.08 (+1.97%)

4.06

-0.16 (-3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners90.67%
Inst Owner Change0.07%
Ins Owners0.56%
Ins Owner Change0.08%
Market Cap316.15M
Revenue(TTM)N/A
Net Income(TTM)-154.08M
Analysts86.32
Price Target16.13 (297.29%)
Short Float %14.6%
Short Ratio9.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.12%
Min EPS beat(2)-4.07%
Max EPS beat(2)18.31%
EPS beat(4)1
Avg EPS beat(4)-5.85%
Min EPS beat(4)-21.61%
Max EPS beat(4)18.31%
EPS beat(8)5
Avg EPS beat(8)0.32%
EPS beat(12)8
Avg EPS beat(12)-1.31%
EPS beat(16)10
Avg EPS beat(16)0.35%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.65%
EPS NY rev (1m)0%
EPS NY rev (3m)9.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-2.8
EYN/A
EPS(NY)-1.98
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.57
OCFYN/A
SpS0
BVpS3.32
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.98%
ROE -59.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.34
Quick Ratio 9.34
Altman-Z -0.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.22%
Cap/Depr(5y)55.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
EPS Next Y32.98%
EPS Next 2Y16.08%
EPS Next 3Y12.32%
EPS Next 5Y14.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-56.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.68%
EBIT Next 3Y-17.91%
EBIT Next 5YN/A
FCF growth 1Y-8.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.79%
OCF growth 3YN/A
OCF growth 5YN/A

SOLID BIOSCIENCES INC / SLDB FAQ

What is the fundamental rating for SLDB stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLDB.


What is the valuation status for SLDB stock?

ChartMill assigns a valuation rating of 0 / 10 to SOLID BIOSCIENCES INC (SLDB). This can be considered as Overvalued.


Can you provide the profitability details for SOLID BIOSCIENCES INC?

SOLID BIOSCIENCES INC (SLDB) has a profitability rating of 1 / 10.


Can you provide the financial health for SLDB stock?

The financial health rating of SOLID BIOSCIENCES INC (SLDB) is 7 / 10.